Pharma Firms Fear Diminished Role In Revised EU Signal Detection Guideline
Executive Summary
The European Medicines Agency recently revised its guideline on signal management to clarify the roles and responsibilities of concerned stakeholders and related terminology, among other things. However, the industry believes that these key aspects need to be further addressed to ensure that the role of marketing authorization holders is not diminished and that there is clarity on procedural aspects, such as calculating the Day 0.
You may also be interested in...
Pharma Buoyed By Preview Of 'Helpful Changes' To EMA's Signal Management Guide
The European Medicines Agency is revising its signal management guideline to clarify several terminologies and offer flexibility to help companies comply with their legal obligation to monitor the revamped EudraVigilance database. The biggest relief for the industry is that the new procedures in the guideline will be initially tested on a small number of products.
EMA To Address Industry Concerns in Revised Signal Management Guideline
The European Medicines Agency is examining the “constructive and pragmatic” feedback it has received on its revised guideline on safety signal detection, which aims to help companies fulfil their new legal obligation to monitor EudraVigilance data and report validated signals within strict timelines.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.